Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome

Peritoneal carcinomatosis, regardless of primary tumour type, has always been a lethal condition. Recently special treatments using cytoreductive surgery with peritonectomy procedures combined with peri-operative intraperitoneal chemotherapy have resulted in long-term survival. Pseudomyxoma peritone...

Full description

Saved in:
Bibliographic Details
Published in:European journal of surgical oncology 2001-04, Vol.27 (3), p.239-243
Main Author: Sugarbaker, P.H.
Format: Article
Language:English
Subjects:
Abdomen
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
appendix cancer
Biological and medical sciences
Chemotherapy, Adjuvant
cytoreduction
Digestive System Surgical Procedures - methods
Female
Fluorouracil - administration & dosage
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Injections, Intraperitoneal
intraperitoneal chemotherapy
Male
Medical sciences
Middle Aged
Mitomycin - administration & dosage
Multivariate Analysis
Peritoneal Neoplasms - drug therapy
Peritoneal Neoplasms - mortality
Peritoneal Neoplasms - pathology
Peritoneal Neoplasms - surgery
Probability
Proportional Hazards Models
pseudomyxoma peritonei
Pseudomyxoma Peritonei - drug therapy
Pseudomyxoma Peritonei - mortality
Pseudomyxoma Peritonei - pathology
Pseudomyxoma Peritonei - surgery
Retrospective Studies
Survival Analysis
Syndrome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Peritoneal carcinomatosis, regardless of primary tumour type, has always been a lethal condition. Recently special treatments using cytoreductive surgery with peritonectomy procedures combined with peri-operative intraperitoneal chemotherapy have resulted in long-term survival. Pseudomyxoma peritonei may be especially appropriate for these aggressive local regional treatments. All patients treated prior to 1999 are presented; patients left with gross residual disease after surgery were not given intraperitoneal chemotherapy, but were later treated with intravenous chemotherapy after cytoreduction. The intraperitoneal chemotherapy was given in the peri-operative period, starting with mitomycin C. For patients whose pathology showed adenomucinosis, intraperitoneal chemotherapy was limited to treatment in the operating theatre with heated mitomycin C. Patients with mucinous adenocarcinoma or pseudomyxoma/adenocarcinoma hybrid had, in addition to mitomycin C, 5 consecutive days of intraperitoneal 5-fluorouracil. A complete cytoreduction was defined as tumour nodules
ISSN:0748-7983
1532-2157
DOI:10.1053/ejso.2000.1038